Trial Profile
A three year follow-up of ranibizumab treatment of exudative age related macular degeneration
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 25 Dec 2015
Price :
$35
*
At a glance
- Drugs Ranibizumab (Primary)
- Indications Age-related macular degeneration
- Focus Therapeutic Use
- 25 Dec 2015 New trial record